--- title: "Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a \"Buy\" rating" type: "News" locale: "en" url: "https://longbridge.com/en/news/281993364.md" description: "Bank of America Securities has lowered the target price for MICROPORT to 13.9 yuan, reiterating a \"Buy\" rating. It expects total revenue in 2025 to be USD 1.105 billion, with a year-on-year increase of 6% after excluding foreign exchange factors. Its \"GloMatrix\" platform has achieved breakeven, and revenue for the fiscal year 2025 is expected to grow by 78.8% to 163.9 million yuan. Due to the exclusion of MICROPORT NEURO from the consolidated financial statements, revenue forecasts for 2026 to 2028 have been reduced by 10.9% to 12.9%. At the same time, gross margin forecasts have been raised by 1.9 to 2.1 percentage points, and operating expense ratio forecasts have been raised by 11.5 to 12.6 percentage points" datetime: "2026-04-08T06:59:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281993364.md) - [en](https://longbridge.com/en/news/281993364.md) - [zh-HK](https://longbridge.com/zh-HK/news/281993364.md) --- # Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating Bank of America Securities published a research report indicating that MicroPort (00853.HK) is expected to record total revenue of USD 1.105 billion in 2025, representing a year-on-year increase of 6% after excluding the impact of exchange rate fluctuations, which is in line with the bank's expectations. It also stated that the group's "GloMatrix" global commercialization platform has achieved breakeven and has become the company's core growth engine, driving revenue growth of 78.8% year-on-year to USD 163.9 million in the fiscal year 2025 after excluding the impact of exchange rate fluctuations. To reflect that MicroPort Neuro (02172.HK) is no longer included in the consolidated financial statements, Bank of America Securities has lowered its revenue forecasts for MicroPort by 10.9%, 11.7%, and 12.9% for the years 2026 to 2028. At the same time, considering the improvement in the product mix, it has raised its gross margin forecasts for 2026 to 2028 by 1.9 to 2.1 percentage points. Based on the rising costs due to overseas business expansion, the bank has also raised its operating expense ratio forecasts by 11.5 to 12.6 percentage points. In response to the improvement in the asset-liability structure, the bank has lowered its financing cost forecast for MicroPort and adjusted its target price from HKD 17 to HKD 13.9, reiterating a "Buy" rating, believing that the company has strong growth potential from overseas markets and surgical robotics business ### Related Stocks - [02160.HK](https://longbridge.com/en/quote/02160.HK.md) - [688351.CN](https://longbridge.com/en/quote/688351.CN.md) - [00853.HK](https://longbridge.com/en/quote/00853.HK.md) - [02172.HK](https://longbridge.com/en/quote/02172.HK.md) - [02252.HK](https://longbridge.com/en/quote/02252.HK.md) - [159883.CN](https://longbridge.com/en/quote/159883.CN.md) - [562600.CN](https://longbridge.com/en/quote/562600.CN.md) - [159898.CN](https://longbridge.com/en/quote/159898.CN.md) - [688016.CN](https://longbridge.com/en/quote/688016.CN.md) ## Related News & Research - [PTA-Adhoc: Gallmetzer HealthCare S.p.A.: Announcement of the publication of financial reports](https://longbridge.com/en/news/283108240.md) - [Ocumetics Reports Improvement in Six Month First-in-Human Results Meaningful Improvements in Patient Quality of Life](https://longbridge.com/en/news/283360869.md) - [Rapid Medical™ Announces FDA Clearance of TIGERTRIEVER™ 25 and First Clinical Cases](https://longbridge.com/en/news/283017446.md) - [MicroPort Scientific (HKG:853) delivers shareholders splendid 119% return over 1 year, surging 8.6% in the last week alone](https://longbridge.com/en/news/272163298.md) - [MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars](https://longbridge.com/en/news/278748555.md)